TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (OTCBB: ORNI) (the “Company”) a world leader in oral health probiotics for humans and companion pets, announced that it has entered into a new three year contract with Central Business USA. Under the terms of the agreement, Central Business USA will be the exclusive distributor of Oragenics’ Oral Care Probiotics for Adults, Kids and Pets in Brazil, Argentina, Paraguay and Uruguay. All products will contain ProBiora3®; the Company’s patented proprietary blend of three probiotics specifically designed for oral health.
Central Business USA is a US based pharmaceutical wholesaler located in Orlando, Florida that provides prescription medication, medical products, vitamins and supplements to the US and South American market. They specialize in "new medications” that are not yet available to hospitals, clinics and doctors.
"This latest agreement reinforces Oragenics’ strategy to continue to expand the oral probiotic product line in the international market. We are confident that in concert with Central Business USA, we can develop a substantial market in these four countries. This partnership positions the Company for further success," stated John N. Bonfiglio PhD, President and CEO of Oragenics.
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in probiotics for oral health for humans and pets and in novel antibiotics against infectious disease. Oragenics, Inc. develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora® and ProBiora® in over 13 countries worldwide. Oragenics, Inc. has established an exclusive worldwide channel collaboration for lantibiotics, a novel class of broad spectrum antibiotics, with Intrexon Corporation, a synthetic biology company.
For more information, visit www.oragenics.com.
Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to our ability to raise additional capital to sustain our operations beyond June 30, 2012 and those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.